GlassScriptPhysician profile
Karie Ann Beasley
NPI 1134601214
$13,471.95
in general payments reported to CMS, 2019-2025
54 companies · $1,655 in 2025
The $1,655 reported for 2025 was more than what 92% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,776 · 2022: $3,997 · 2023: $3,344 · 2024: $700 · 2025: $1,655.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,690 · Education: $9.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,689.96 |
| Education | $9.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,648.28 | 2021-2025 | |
| Gilead Sciences, INC. | $1,119.82 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,015.17 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Viiv Healthcare Company | $954.32 | 2021-2024 | Dovato, Rukobia, Cabenuva |
| Amgen INC. | $770.22 | 2021-2023 | Repatha, Otezla, Prolia |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $728.07 | 2021-2025 | Caplyta |
| Novo Nordisk INC | $686.08 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $526.40 | 2021-2024 | Jardiance |
| Lundbeck LLC | $495.39 | 2021-2025 | Rexulti, Vyepti |
| Pfizer INC. | $454.37 | 2021-2025 | |
| Lilly USA, LLC | $407.49 | 2021-2024 | Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $398.49 | 2021-2025 | Trintellix, Gattex |
| Alkermes, INC. | $375.94 | 2021-2025 | Aristada, Lybalvi |
| Sunovion Pharmaceuticals INC. | $342.49 | 2021-2022 | |
| Janssen Products, LP | $323.42 | 2021-2022 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karie Beasley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.